Retatrutide is a triple-agonist incretin mimetic that simultaneously targets the GLP-1, GIP and glucagon receptors, making it a leading model compound for next-generation metabolic and energy-balance research.
$150.00
Bestseller
30-day risk-free guarantee. Free US shipping.
Bundle & Save
1
Triple-receptor model: Engages GLP-1, GIP and glucagon receptors for multi-pathway metabolic assays.
Energy-balance research: Used to investigate appetite-signalling and energy-expenditure pathways in vitro.
Incretin studies: A reference incretin mimetic for comparative receptor-signalling work.